Investigating a new therapy to prevent cognitive decline in Alzheimer's disease
Official title: Tumor susceptibility gene 101, a new microglial therapy candidate for Alzheimer’s disease to prevent cognitive decline
Funded at Mayo Clinic Jacksonville · NIH-10710931 · Data updated 2026-11-12
This study is exploring a new way to help people with Alzheimer's by changing a gene that affects brain immune cells, which could help clear out harmful proteins and improve thinking and memory.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $1,994,202 |
| NIH project number | 1RF1AG082704-01 |
| Project ID | NIH-10710931 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease, particularly those with early cognitive decline.
✕Less likely to help
Patients with advanced Alzheimer's disease or those with other forms of dementia may not benefit from this research.
What this research studies
This research focuses on a potential new treatment for Alzheimer's disease by targeting a specific gene involved in the function of microglia, the brain's immune cells. The study aims to manipulate the secretion of extracellular vesicles from microglia to reduce the accumulation of toxic proteins associated with Alzheimer's, such as tau. Using a mouse model of the disease, researchers will assess cognitive function and the progression of neurodegeneration after altering the gene's activity. The findings could lead to innovative therapies that improve brain health and cognitive abilities in Alzheimer's patients.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking therapy that slows or prevents cognitive decline in individuals with Alzheimer's disease.
How similar studies have gone: Other research has shown promise in targeting microglial functions to mitigate neurodegeneration, suggesting that this approach could be effective.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Ikezu, Seiko — Mayo Clinic Jacksonville
- Study coordinator: Ikezu, Seiko
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
NGF Metabolism as a biomarker for cognitive decline in familial Alzheimer's disease
Researchers are studying whether patterns in nerve growth factor pathways in blood and CSF can signal early, preclinical stages of Alzheimer's in people with genetic risk.
-
NGF metabolism as an early biomarker for cognitive decline in familial Alzheimer's disease
This project tests whether NGF pathway proteins in blood and CSF can signal early, preclinical changes in people with familial Alzheimer’s disease.
-
NGF Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's Disease
This project looks at nerve growth factor pathways in people with a genetic form of Alzheimer's to see if blood and spinal fluid markers can identify early brain changes before symptoms appear.
-
Remote monitoring of Alzheimer’s changes in adults with Down syndrome
A study tests remote (at-home) ways to track Alzheimer’s-related thinking changes in adults with Down syndrome.
-
Tumor Susceptibility Gene 101: a microglial therapy approach to protect memory in Alzheimer’s disease
A Mayo Clinic team is studying a protein called TSG101 in brain immune cells to slow or prevent cognitive decline in Alzheimer’s disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.